Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 195

1.

Chromatin-informed inference of transcriptional programs in gynecologic and basal breast cancers.

Osmanbeyoglu HU, Shimizu F, Rynne-Vidal A, Alonso-Curbelo D, Chen HA, Wen HY, Yeung TL, Jelinic P, Razavi P, Lowe SW, Mok SC, Chiosis G, Levine DA, Leslie CS.

Nat Commun. 2019 Sep 25;10(1):4369. doi: 10.1038/s41467-019-12291-6.

2.

Lymphocyte-specific kinase expression is a prognostic indicator in ovarian cancer and correlates with a prominent B cell transcriptional signature.

Hinchcliff E, Paquette C, Roszik J, Kelting S, Stoler MH, Mok SC, Yeung TL, Zhang Q, Yates M, Peng W, Hwu P, Jazaeri A.

Cancer Immunol Immunother. 2019 Sep;68(9):1515-1526. doi: 10.1007/s00262-019-02385-x. Epub 2019 Sep 12.

PMID:
31515669
3.

Anticancer Immunotherapy by MFAP5 Blockade Inhibits Fibrosis and Enhances Chemosensitivity in Ovarian and Pancreatic Cancer.

Yeung TL, Leung CS, Yip KP, Sheng J, Vien L, Bover LC, Birrer MJ, Wong STC, Mok SC.

Clin Cancer Res. 2019 Jul 22. doi: 10.1158/1078-0432.CCR-19-0187. [Epub ahead of print]

PMID:
31332047
4.

ISG15 Promotes ERK1 ISGylation, CD8+ T Cell Activation and Suppresses Ovarian Cancer Progression.

Yeung TL, Tsai CC, Leung CS, Au Yeung CL, Thompson MS, Lu KH, Freedman RS, Birrer MJ, Wong KK, Mok SC.

Cancers (Basel). 2018 Nov 22;10(12). pii: E464. doi: 10.3390/cancers10120464.

5.

Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens.

Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, Wang Y, Baggerly K, Ram P, Lopez-Berestein G, Liu J, Mok SC, Cohen L, Lutgendorf SK, Cole SW, Sood AK.

JCI Insight. 2018 Jun 7;3(11). pii: 122389. doi: 10.1172/jci.insight.122389. eCollection 2018 Jun 7. No abstract available.

6.

Systematic Identification of Druggable Epithelial-Stromal Crosstalk Signaling Networks in Ovarian Cancer.

Yeung TL, Sheng J, Leung CS, Li F, Kim J, Ho SY, Matzuk MM, Lu KH, Wong STC, Mok SC.

J Natl Cancer Inst. 2019 Mar 1;111(3):272-282. doi: 10.1093/jnci/djy097. Erratum in: J Natl Cancer Inst. 2018 Oct 1;110(10):1146.

7.

Recommendations and Choices for BRCA Mutation Carriers at Risk for Ovarian Cancer: A Complicated Decision.

Lewis KE, Lu KH, Klimczak AM, Mok SC.

Cancers (Basel). 2018 Feb 21;10(2). pii: E57. doi: 10.3390/cancers10020057. Review.

8.

Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance.

Leung CS, Yeung TL, Yip KP, Wong KK, Ho SY, Mangala LS, Sood AK, Lopez-Berestein G, Sheng J, Wong ST, Birrer MJ, Mok SC.

J Clin Invest. 2018 Feb 1;128(2):589-606. doi: 10.1172/JCI95200. Epub 2017 Dec 18.

9.

Functional prediction of long non-coding RNAs in ovarian cancer-associated fibroblasts indicate a potential role in metastasis.

Vafaee F, Colvin EK, Mok SC, Howell VM, Samimi G.

Sci Rep. 2017 Sep 4;7(1):10374. doi: 10.1038/s41598-017-10869-y.

10.

Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens.

Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, Wang Y, Baggerly K, Ram P, Lopez-Berestein G, Liu J, Mok SC, Cohen L, Lutgendorf SK, Cole SW, Sood AK.

JCI Insight. 2017 Aug 17;2(16). pii: 93076. doi: 10.1172/jci.insight.93076. eCollection 2017 Aug 17.

11.

Positive family history of aortic dissection dramatically increases dissection risk in family members.

Ma WG, Chou AS, Mok SCM, Ziganshin BA, Charilaou P, Zafar MA, Sieller RS, Tranquilli M, Rizzo JA, Elefteriades JA.

Int J Cardiol. 2017 Aug 1;240:132-137. doi: 10.1016/j.ijcard.2017.04.080. Epub 2017 Apr 25.

PMID:
28502736
12.

Immune Microenvironment in Microsatellite-Instable Endometrial Cancers: Hereditary or Sporadic Origin Matters.

Pakish JB, Zhang Q, Chen Z, Liang H, Chisholm GB, Yuan Y, Mok SC, Broaddus RR, Lu KH, Yates MS.

Clin Cancer Res. 2017 Aug 1;23(15):4473-4481. doi: 10.1158/1078-0432.CCR-16-2655. Epub 2017 Mar 6.

13.

Mesothelial-to-mesenchymal transition as a possible therapeutic target in peritoneal metastasis of ovarian cancer.

Rynne-Vidal A, Au-Yeung CL, Jiménez-Heffernan JA, Pérez-Lozano ML, Cremades-Jimeno L, Bárcena C, Cristóbal-García I, Fernández-Chacón C, Yeung TL, Mok SC, Sandoval P, López-Cabrera M.

J Pathol. 2017 Jun;242(2):140-151. doi: 10.1002/path.4889. Epub 2017 Apr 3.

14.

ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells.

Yeung TL, Leung CS, Wong KK, Gutierrez-Hartmann A, Kwong J, Gershenson DM, Mok SC.

Oncotarget. 2017 Mar 7;8(10):16951-16963. doi: 10.18632/oncotarget.15208.

15.

Twenty-five year outcomes following composite graft aortic root replacement.

Mok SC, Ma WG, Mansour A, Charilaou P, Chou AS, Peterss S, Tranquilli M, Ziganshin BA, Elefteriades JA.

J Card Surg. 2017 Feb;32(2):99-109. doi: 10.1111/jocs.12875. Epub 2016 Dec 14.

PMID:
27966257
16.

Targeting Stromal Glutamine Synthetase in Tumors Disrupts Tumor Microenvironment-Regulated Cancer Cell Growth.

Yang L, Achreja A, Yeung TL, Mangala LS, Jiang D, Han C, Baddour J, Marini JC, Ni J, Nakahara R, Wahlig S, Chiba L, Kim SH, Morse J, Pradeep S, Nagaraja AS, Haemmerle M, Kyunghee N, Derichsweiler M, Plackemeier T, Mercado-Uribe I, Lopez-Berestein G, Moss T, Ram PT, Liu J, Lu X, Mok SC, Sood AK, Nagrath D.

Cell Metab. 2016 Nov 8;24(5):685-700. doi: 10.1016/j.cmet.2016.10.011.

17.

Monitoring of ovarian cancer cell invasion in real time with frequency-dependent impedance measurement.

Lo CM, Lo JC, Sato PY, Yeung TL, Mok SC, Yip KP.

Am J Physiol Cell Physiol. 2016 Dec 1;311(6):C1040-C1047. doi: 10.1152/ajpcell.00211.2016. Epub 2016 Oct 26.

18.

Do Familial Aortic Dissections Tend to Occur at the Same Age?

Chou AS, Ma WG, Mok SC, Ziganshin BA, Peterss S, Rizzo JA, Tranquilli M, Elefteriades JA.

Ann Thorac Surg. 2017 Feb;103(2):546-550. doi: 10.1016/j.athoracsur.2016.06.007. Epub 2016 Aug 25.

PMID:
27570161
19.

Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1.

Au Yeung CL, Co NN, Tsuruga T, Yeung TL, Kwan SY, Leung CS, Li Y, Lu ES, Kwan K, Wong KK, Schmandt R, Lu KH, Mok SC.

Nat Commun. 2016 Mar 29;7:11150. doi: 10.1038/ncomms11150.

20.

Letter from the New Editor-in-Chief.

Mok SC.

Cancers (Basel). 2016 Jan 6;8(1). pii: E9. doi: 10.3390/cancers8010009.

21.

Targeting Stromal-Cancer Cell Crosstalk Networks in Ovarian Cancer Treatment.

Yeung TL, Leung CS, Li F, Wong SS, Mok SC.

Biomolecules. 2016 Jan 6;6(1):3. doi: 10.3390/biom6010003. Review.

22.

Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer.

Moran-Jones K, Gloss BS, Murali R, Chang DK, Colvin EK, Jones MD, Yuen S, Howell VM, Brown LM, Wong CW, Spong SM, Scarlett CJ, Hacker NF, Ghosh S, Mok SC, Birrer MJ, Samimi G.

Oncotarget. 2015 Dec 29;6(42):44551-62. doi: 10.18632/oncotarget.6082.

23.

KDM4B and KDM4A promote endometrial cancer progression by regulating androgen receptor, c-myc, and p27kip1.

Qiu MT, Fan Q, Zhu Z, Kwan SY, Chen L, Chen JH, Ying ZL, Zhou Y, Gu W, Wang LH, Cheng WW, Zeng J, Wan XP, Mok SC, Wong KK, Bao W.

Oncotarget. 2015 Oct 13;6(31):31702-20. doi: 10.18632/oncotarget.5165.

24.

Cellular and molecular processes in ovarian cancer metastasis. A Review in the Theme: Cell and Molecular Processes in Cancer Metastasis.

Yeung TL, Leung CS, Yip KP, Au Yeung CL, Wong ST, Mok SC.

Am J Physiol Cell Physiol. 2015 Oct 1;309(7):C444-56. doi: 10.1152/ajpcell.00188.2015. Epub 2015 Jul 29. Review.

25.

CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks.

Guo F, Wang Y, Liu J, Mok SC, Xue F, Zhang W.

Oncogene. 2016 Feb 18;35(7):816-26. doi: 10.1038/onc.2015.139. Epub 2015 May 11. Review.

PMID:
25961926
26.

CAF reprogramming inhibits ovarian cancer progression.

Yeung TL, Leung CS, Mok SC.

Cell Cycle. 2014;13(24):3783-4. doi: 10.4161/15384101.2014.988106. No abstract available.

27.

Calcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential.

Leung CS, Yeung TL, Yip KP, Pradeep S, Balasubramanian L, Liu J, Wong KK, Mangala LS, Armaiz-Pena GN, Lopez-Berestein G, Sood AK, Birrer MJ, Mok SC.

Nat Commun. 2014 Oct 3;5:5092. doi: 10.1038/ncomms6092.

28.

Loss of LKB1 in high-grade endometrial carcinoma: LKB1 is a novel transcriptional target of p53.

Co NN, Iglesias D, Celestino J, Kwan SY, Mok SC, Schmandt R, Lu KH.

Cancer. 2014 Nov 15;120(22):3457-68. doi: 10.1002/cncr.28854. Epub 2014 Jul 16.

29.

KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.

Tsang YT, Deavers MT, Sun CC, Kwan SY, Kuo E, Malpica A, Mok SC, Gershenson DM, Wong KK.

J Pathol. 2013 Dec;231(4):449-56. doi: 10.1002/path.4252.

30.

Human omental-derived adipose stem cells increase ovarian cancer proliferation, migration, and chemoresistance.

Nowicka A, Marini FC, Solley TN, Elizondo PB, Zhang Y, Sharp HJ, Broaddus R, Kolonin M, Mok SC, Thompson MS, Woodward WA, Lu K, Salimian B, Nagrath D, Klopp AH.

PLoS One. 2013 Dec 2;8(12):e81859. doi: 10.1371/journal.pone.0081859. eCollection 2013.

31.

Gene expression signature of normal cell-of-origin predicts ovarian tumor outcomes.

Merritt MA, Bentink S, Schwede M, Iwanicki MP, Quackenbush J, Woo T, Agoston ES, Reinhardt F, Crum CP, Berkowitz RS, Mok SC, Witt AE, Jones MA, Wang B, Ince TA.

PLoS One. 2013 Nov 26;8(11):e80314. doi: 10.1371/journal.pone.0080314. eCollection 2013.

32.

FGF18 as a prognostic and therapeutic biomarker in ovarian cancer.

Wei W, Mok SC, Oliva E, Kim SH, Mohapatra G, Birrer MJ.

J Clin Invest. 2013 Oct;123(10):4435-48. doi: 10.1172/JCI70625. Epub 2013 Sep 9.

33.

TGF-β modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment.

Yeung TL, Leung CS, Wong KK, Samimi G, Thompson MS, Liu J, Zaid TM, Ghosh S, Birrer MJ, Mok SC.

Cancer Res. 2013 Aug 15;73(16):5016-28. doi: 10.1158/0008-5472.CAN-13-0023. Epub 2013 Jul 3.

34.

Poor survival with wild-type TP53 ovarian cancer?

Wong KK, Izaguirre DI, Kwan SY, King ER, Deavers MT, Sood AK, Mok SC, Gershenson DM.

Gynecol Oncol. 2013 Sep;130(3):565-9. doi: 10.1016/j.ygyno.2013.06.016. Epub 2013 Jun 22.

35.

Crystal structure of a compact α-amylase from Geobacillus thermoleovorans.

Mok SC, Teh AH, Saito JA, Najimudin N, Alam M.

Enzyme Microb Technol. 2013 Jun 10;53(1):46-54. doi: 10.1016/j.enzmictec.2013.03.009. Epub 2013 Mar 28.

PMID:
23683704
36.

PAX2 Expression in Ovarian Cancer.

Song H, Kwan SY, Izaguirre DI, Zu Z, Tsang YT, Tung CS, King ER, Mok SC, Gershenson DM, Wong KK.

Int J Mol Sci. 2013 Mar 15;14(3):6090-105. doi: 10.3390/ijms14036090.

37.

Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer.

Zaid TM, Yeung TL, Thompson MS, Leung CS, Harding T, Co NN, Schmandt RS, Kwan SY, Rodriguez-Aguay C, Lopez-Berestein G, Sood AK, Wong KK, Birrer MJ, Mok SC.

Clin Cancer Res. 2013 Feb 15;19(4):809-20. doi: 10.1158/1078-0432.CCR-12-2736. Epub 2013 Jan 23.

38.

Identification of a potential ovarian cancer stem cell gene expression profile from advanced stage papillary serous ovarian cancer.

Vathipadiekal V, Saxena D, Mok SC, Hauschka PV, Ozbun L, Birrer MJ.

PLoS One. 2012;7(1):e29079. doi: 10.1371/journal.pone.0029079. Epub 2012 Jan 17.

39.

Identification of novel therapeutic targets in microdissected clear cell ovarian cancers.

Stany MP, Vathipadiekal V, Ozbun L, Stone RL, Mok SC, Xue H, Kagami T, Wang Y, McAlpine JN, Bowtell D, Gout PW, Miller DM, Gilks CB, Huntsman DG, Ellard SL, Wang YZ, Vivas-Mejia P, Lopez-Berestein G, Sood AK, Birrer MJ.

PLoS One. 2011;6(7):e21121. doi: 10.1371/journal.pone.0021121. Epub 2011 Jul 6.

40.

The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma.

King ER, Zu Z, Tsang YT, Deavers MT, Malpica A, Mok SC, Gershenson DM, Wong KK.

Gynecol Oncol. 2011 Oct;123(1):13-8. doi: 10.1016/j.ygyno.2011.06.016. Epub 2011 Jul 2.

41.

The anterior gradient homolog 3 (AGR3) gene is associated with differentiation and survival in ovarian cancer.

King ER, Tung CS, Tsang YT, Zu Z, Lok GT, Deavers MT, Malpica A, Wolf JK, Lu KH, Birrer MJ, Mok SC, Gershenson DM, Wong KK.

Am J Surg Pathol. 2011 Jun;35(6):904-12. doi: 10.1097/PAS.0b013e318212ae22.

42.

Differential hRad17 expression by histologic subtype of ovarian cancer.

Young JL, Koon EC, Kwong J, Welch WR, Muto MG, Berkowitz RS, Mok SC.

J Ovarian Res. 2011 Mar 30;4(1):6. doi: 10.1186/1757-2215-4-6.

43.

Dysregulation of microRNA-204 mediates migration and invasion of endometrial cancer by regulating FOXC1.

Chung TK, Lau TS, Cheung TH, Yim SF, Lo KW, Siu NS, Chan LK, Yu MY, Kwong J, Doran G, Barroilhet LM, Ng AS, Wong RR, Wang VW, Mok SC, Smith DI, Berkowitz RS, Wong YF.

Int J Cancer. 2012 Mar 1;130(5):1036-45. doi: 10.1002/ijc.26060. Epub 2011 Jun 2.

44.

Microscopic and early-stage ovarian cancers in BRCA1/2 mutation carriers: building a model for early BRCA-associated tumorigenesis.

Yates MS, Meyer LA, Deavers MT, Daniels MS, Keeler ER, Mok SC, Gershenson DM, Lu KH.

Cancer Prev Res (Phila). 2011 Mar;4(3):463-70. doi: 10.1158/1940-6207.CAPR-10-0266. Epub 2011 Jan 28.

45.

C terminus of Clostridium perfringens enterotoxin downregulates CLDN4 and sensitizes ovarian cancer cells to Taxol and Carboplatin.

Gao Z, Xu X, McClane B, Zeng Q, Litkouhi B, Welch WR, Berkowitz RS, Mok SC, Garner EI.

Clin Cancer Res. 2011 Mar 1;17(5):1065-74. doi: 10.1158/1078-0432.CCR-10-1644. Epub 2010 Dec 1.

46.

BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas.

Wong KK, Tsang YT, Deavers MT, Mok SC, Zu Z, Sun C, Malpica A, Wolf JK, Lu KH, Gershenson DM.

Am J Pathol. 2010 Oct;177(4):1611-7. doi: 10.2353/ajpath.2010.100212. Epub 2010 Aug 27.

47.

Up-regulation of stromal versican expression in advanced stage serous ovarian cancer.

Ghosh S, Albitar L, LeBaron R, Welch WR, Samimi G, Birrer MJ, Berkowitz RS, Mok SC.

Gynecol Oncol. 2010 Oct;119(1):114-20. doi: 10.1016/j.ygyno.2010.05.029. Epub 2010 Jul 8.

48.

Activated networking of platelet activating factor receptor and FAK/STAT1 induces malignant potential in BRCA1-mutant at-risk ovarian epithelium.

Zhang L, Wang D, Jiang W, Edwards D, Qiu W, Barroilhet LM, Rho JH, Jin L, Seethappan V, Vitonis A, Wang J, Mok SC, Crum C, Cramer DW, Ye B.

Reprod Biol Endocrinol. 2010 Jun 24;8:74. doi: 10.1186/1477-7827-8-74.

49.

A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2.

Mok SC, Bonome T, Vathipadiekal V, Bell A, Johnson ME, Wong KK, Park DC, Hao K, Yip DK, Donninger H, Ozbun L, Samimi G, Brady J, Randonovich M, Pise-Masison CA, Barrett JC, Wong WH, Welch WR, Berkowitz RS, Birrer MJ.

Cancer Cell. 2009 Dec 8;16(6):521-32. doi: 10.1016/j.ccr.2009.10.018.

50.

Immunopathogenesis of ovarian cancer.

Thompson MS, Mok SC.

Minerva Med. 2009 Oct;100(5):357-70. Review.

PMID:
19910889

Supplemental Content

Support Center